Amsterdam, The Netherlands, August 26, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces its unaudited financial results for the six months ended June 30, 2016, which have been prepared in accordance with the IAS 34 “Interim Financial Reporting” as adopted by the European Union.
Operating highlights (including post period end)
Positive results announced on the primary endpoint from the single dose Phase II CR-AIR-007 trial (ATIR101™)
Decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101™ in blood cancers – submission on course for Q1 2017
PCT appointed for US manufacture of ATIR101™ for Phase III trial
Orphan Drug Designation for ATIR101™ further expanded to include treatment in a hematopoietic stem cell transplantation
Supervisory Board strengthened with appointment of Dr. Robert Soiffer and Mr. Berndt Modig
Partnership announced with The Leukemia & Lymphoma Society around the development of ATIR101™ in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients
Preparations to commence the CR-AIR-009 (ATIR101™) Phase III trial ongoing with initiation expected on track by end 2016
Second dose CR-AIR-008 Phase II trial ongoing – safety read-out now expected in Q1 2017
Initiation of ATIR201™ Phase I/II thalassemia trial (CR-BD-001) on track for patient enrollment in Q4 2016
Last updated on: 27/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.